FP19-6 Excess Mortality in Mothers of Patients with Polycystic Ovary Syndrome

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: FP19-Female Reproductive Endocrinology
Sunday, June 16, 2013: 10:45 AM-11:15 AM
Presentation Start Time: 11:10 AM
Room 102 (Moscone Center)

Poster Board SUN-500
Yvonne V. Louwers*1, Marieke Roest-Schalken1, Jeanine Roeters van Lennep1, Marjan van den Berg2 and Eric J.G. Sijbrands1
1Erasmus MC University Medical Center, Rotterdam, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands
Aim and background Polycystic ovary syndrome (PCOS) has a familial or heritable nature. PCOS is associated with type 2 diabetes mellitus and probably with cardiovascular disease. Parents of PCOS patients may therefore have a similar susceptibility to develop these chronic diseases and this might reduce their life expectancy. In the present study, we determined the all-cause mortality of parents of PCOS patients.

Methods Standard mortality ratio (SMR) was calculated of 946 mothers and 902 fathers as the ratio of the observed mortality of the parents to the expected mortality in the general population standardized for age, gender and calendar period.

Results In 62,693 person-years we observed 302 deaths. Overall mortality risk of the parents was not increased compared to the general Dutch population. However, mothers above 60 years of age had significant excess mortality of 1.496 (95%CI 1.15 to 1.92). The prevalence of type 2 diabetes mellitus as well as cardiovascular disease was much higher in mothers of PCOS patients compared to those of the general population of the same age. Mothers with type 2 diabetes mellitus and CVD clearly had excess mortality: the SMR’s were 2.22 (95%CI 1.39 to 3.36) and 1.55 (95% CI 1.10 to 2.13), respectively. We did not observe excess mortality among the fathers.

Conclusion Excess mortality was observed among the mothers of PCOS patients, largely based on severe mortality risk of the mothers with type 2 diabetes mellitus. Therefore, we advise screening of the mothers of PCOS patients to ensure that early preventive and therapeutic measures are taken.

Nothing to Disclose: YVL, MR, JR, MV, EJGS

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

<< Previous Abstract | Next Abstract